Abstract
The conventional chemotherapy agent, doxorubicin, is of limited clinical use because of its systemic toxicity toward normal healthy tissue. A new doxorubicin conjugate with α-linolenic acid showed good anti-tumor activity with lower toxicity than free doxorubicin and exhibited an active tumor-targeting profile due to the introduction of α-linolenic acid which might be an effective tumor-targeting moiety for the modification of chemotherapeutics.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Antineoplastic Agents / chemical synthesis*
-
Antineoplastic Agents / pharmacology*
-
Breast Neoplasms / drug therapy*
-
Breast Neoplasms / metabolism
-
Breast Neoplasms / mortality
-
Breast Neoplasms / pathology
-
Cell Line, Tumor
-
Cell Survival / drug effects
-
Dose-Response Relationship, Drug
-
Doxorubicin / analogs & derivatives*
-
Doxorubicin / chemical synthesis
-
Doxorubicin / pharmacology*
-
Endocytosis / drug effects
-
Female
-
Humans
-
Inhibitory Concentration 50
-
Mice
-
Mice, SCID
-
Molecular Targeted Therapy
-
Neoplasm Transplantation
-
Survival Rate
-
Tumor Burden / drug effects
-
Xenograft Model Antitumor Assays
-
alpha-Linolenic Acid / chemistry*
Substances
-
Antineoplastic Agents
-
alpha-Linolenic Acid
-
Doxorubicin